Fluorescent sensor for thiols: Deprotection of nonfluorescent 1 by thiols (R′SH) proceeds rapidly and near‐quantitatively in aqueous solution (pH 7.4) to produce highly fluorescent 2. Assays ...performed in the presence of 1 provide a rapid and simple method for the determination of inhibitory constants for inhibitors such as donepezil toward acetyl‐ and butyrylcholinesterases.
Highly selective detection of H2O2 through a non‐oxidative mechanism has been achieved by desulfonylation of 1 to the corresponding fluorescein. This approach has been used for the intracellular ...formation of H2O2 in algal cells by using the acetyl derivatives of 1 as fluorescent probes.
Fluoreszenzsensor für Thiole: Das Entschützen von nichtfluoreszierendem 1 durch Thiole (R′SH) verläuft in wässriger Lösung (pH 7.4) rasch und liefert nahezu quantitativ stark fluoreszierendes 2. ...Assays in Gegenwart von 1 sind somit eine schnelle und einfache Methode, um die Inhibierungskonstanten von Inhibitoren wie Donepezil gegenüber Acetyl‐ und Butyrylcholinesterasen zu bestimmen.
Die hochselektive Detektion von H2O2 beruht auf der Desulfonylierung von 1 zum Fluorescein‐Derivat nach einem nichtoxidativen Mechanismus. Mit dieser Methode wurde die Bildung von H2O2 in Algenzellen ...untersucht; dabei kamen Acetylderivate von 1 als Fluoreszenzsonden zum Einsatz.
Plasmablastic lymphoma (PBL) is a rare aggressive B-cell lymphoproliferative disorder that is strongly associated with immunodeficiency, most often with human immunodeficiency virus (HIV) and ...Epstein-Barr virus (EBV) infection, and that mainly occurs in the oral cavity. Although some clinical features can lead to a diagnosis, PBL in an extraoral site is difficult to suspect clinically in a patient who is HIV negative. The small intestine as a site of PBL has also been described very rarely. We herein present a rare case of PBL of the small intestine in an 85-year-old HIV- and EBV-negative male.
To evaluate the cost-effectiveness of risankizumab versus other biologic treatments (adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, and guselkumab) of moderate-to-severe ...psoriasis in Japan.
A Markov cohort-level model was constructed to estimate quality-adjusted life years (QALYs) and costs for each treatment over a lifetime horizon. The model simulated patients' transition through one line of active biologic therapy followed by best supportive care and death. Transition probabilities were informed by network meta-analyses of Psoriasis Activity and Severity Index responses and adverse event-related discontinuation in clinical trials, as well as published real-world evidence and national mortality rates. Costs were evaluated from the health system, societal, and patient out-of-pocket perspectives.
Risankizumab was expected to provide 0.30-0.89 additional QALYs versus comparator biologics. Under the health system perspective, incremental cost-effectiveness ratios (ICERs) of risankizumab ranged from ¥2,545,812/QALY versus ustekinumab to ¥6,077,134/QALY versus adalimumab. Societal ICERs were lower, ranging from ¥921,770/QALY to ¥4,350,879/QALY. From the patient perspective, risankizumab was estimated to be cost-saving versus four comparators and was associated with ICERs of <¥500,000/QALY versus the remaining comparators.
Risankizumab was associated with higher QALYs and, based on typical willingness-to-pay benchmarks (¥5-6.7 million/QALY), considered cost-effective versus other biologics for the treatment of psoriasis in Japan.
PDF
